Bank of America Corp DE raised its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 12.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,191 shares of the medical instruments supplier’s stock after buying an additional 3,344 shares during the quarter. Bank of America Corp DE owned about 0.08% of AngioDynamics worth $649,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Piedmont Investment Advisors LLC bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $191,000. Crossmark Global Holdings Inc. bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $205,000. Sun Life Financial INC bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $231,000. SG Americas Securities LLC bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $336,000. Finally, Perkins Capital Management Inc. bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $844,000.

In other AngioDynamics news, CFO Michael Greiner sold 1,939 shares of the company’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $21.53, for a total value of $41,746.67. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 2.80% of the company’s stock.

ANGO has been the topic of a number of research reports. BidaskClub upgraded AngioDynamics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 24th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Four analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $18.44.

Shares of NASDAQ:ANGO opened at $21.01 on Wednesday. AngioDynamics, Inc. has a fifty-two week low of $15.16 and a fifty-two week high of $24.49. The firm has a market capitalization of $805.91 million, a price-to-earnings ratio of 28.39 and a beta of 0.75. The company has a current ratio of 2.64, a quick ratio of 1.55 and a debt-to-equity ratio of 0.16.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The company had revenue of $85.34 million during the quarter, compared to the consensus estimate of $84.05 million. During the same quarter last year, the company earned $0.13 earnings per share. The business’s revenue was down .1% on a year-over-year basis. As a group, research analysts predict that AngioDynamics, Inc. will post 0.85 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Bank of America Corp DE Has $649,000 Position in AngioDynamics, Inc. (ANGO)” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/11/21/bank-of-america-corp-de-has-649000-position-in-angiodynamics-inc-ango.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.